Rollig C, Schliemann C, Ruhnke L, Fransecky L, et al. Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study. Br J Haematol 2024;204:2254-2258.
PMID: 38593353